- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-IL17 therapies for psoriasis
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 19, Issue 1, Pages 45-54
Publisher
Informa UK Limited
Online
2018-12-01
DOI
10.1080/14712598.2019.1555235
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled Phase 3b Study of Patients with Moderate-to-Severe Genital Psoriasis
- (2018) C. Ryan et al. BRITISH JOURNAL OF DERMATOLOGY
- Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3
- (2018) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)
- (2018) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Maintenance of Skin Clearance With Ixekizumab Treatment of Psoriasis: Three-Year Results From the UNCOVER-3 Study
- (2018) Craig Leonardi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
- (2018) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis
- (2018) Claus Zachariae et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
- (2018) R. Bissonnette et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials
- (2018) A.B. Gottlieb et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota
- (2018) Ce Tang et al. NATURE IMMUNOLOGY
- Bimekizumab for the treatment of psoriatic disease
- (2018) Nicola E. Natsis et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Review of IL-17 inhibitors for psoriasis
- (2017) Mina Amin et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease
- (2017) Megan Hohenberger et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Psoriasis and suicidality: A systematic review and meta-analysis
- (2017) Sanminder Singh et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
- (2017) Alice Gottlieb et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
- (2017) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
- (2017) Jerry Bagel et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
- (2017) A. Menter et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
- (2017) Peter Nash et al. LANCET
- Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
- (2017) Iain B McInnes et al. RHEUMATOLOGY
- Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis
- (2017) Caleb Jeon et al. Human Vaccines & Immunotherapeutics
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
- (2016) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents
- (2016) Andrea Chiricozzi et al. Expert Opinion On Drug Safety
- Safety of secukinumab in the treatment of psoriasis
- (2016) Andrew Blauvelt Expert Opinion On Drug Safety
- A Review of Psoriasis, Therapies, and Suicide
- (2016) Melinda Gooderham et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
- (2016) Kristian Reich et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)
- (2016) Hidehisa Saeki et al. JOURNAL OF DERMATOLOGY
- Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study
- (2016) Shinichi Imafuku et al. JOURNAL OF DERMATOLOGY
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis
- (2016) Philip J. Mease et al. Arthritis & Rheumatology
- Psoriasis
- (2016) Jacqueline E. Greb et al. Nature Reviews Disease Primers
- Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
- (2015) D. Thaçi et al. BRITISH JOURNAL OF DERMATOLOGY
- Interleukin-17 Antagonists in the Treatment of Psoriasis
- (2015) Shivani Felicia Chandrakumar et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
- (2015) Florence J. Dalgard et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
- (2015) Ulrich Mrowietz et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
- (2014) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- The role of IL-17 in psoriasis
- (2014) Mona Malakouti et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
- (2014) Charles W. Lynde et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment
- (2014) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
- (2014) C. Paul et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
- (2014) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis
- (2013) Emmilia A. Dowlatshahi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
- (2013) Michelle A. Lowes et al. TRENDS IN IMMUNOLOGY
- New insights of T cells in the pathogenesis of psoriasis
- (2012) Yihua Cai et al. Cellular & Molecular Immunology
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
- (2012) Rosa Parisi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Targeting IL-17 and TH17 cells in chronic inflammation
- (2012) Pierre Miossec et al. NATURE REVIEWS DRUG DISCOVERY
- T helper 17 cell heterogeneity and pathogenicity in autoimmune disease
- (2011) Kamran Ghoreschi et al. TRENDS IN IMMUNOLOGY
- Biological therapy of psoriasis
- (2010) Emanual Maverakis et al. INDIAN JOURNAL OF DERMATOLOGY
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now